- Home
- PEPG vs STTK Comparison
PEPG vs STTK Comparison
Compare PEPG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- STTK
- Stock Information
- Founded
- PEPG 2018
- STTK 2016
- Country
- PEPG United States
- STTK United States
- Employees
- PEPG N/A
- STTK N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- STTK Health Care
- Exchange
- PEPG Nasdaq
- STTK Nasdaq
- Market Cap
- PEPG 45.5M
- STTK 37.6M
- IPO Year
- PEPG 2022
- STTK 2020
- Fundamental
- Price
- PEPG $1.22
- STTK $0.83
- Analyst Decision
- PEPG Buy
- STTK Hold
- Analyst Count
- PEPG 3
- STTK 4
- Target Price
- PEPG $7.67
- STTK $3.00
- AVG Volume (30 Days)
- PEPG 290.3K
- STTK 401.7K
- Earning Date
- PEPG 08-07-2025
- STTK 07-31-2025
- Dividend Yield
- PEPG N/A
- STTK N/A
- EPS Growth
- PEPG N/A
- STTK N/A
- EPS
- PEPG N/A
- STTK N/A
- Revenue
- PEPG N/A
- STTK $4,606,000.00
- Revenue This Year
- PEPG N/A
- STTK N/A
- Revenue Next Year
- PEPG N/A
- STTK N/A
- P/E Ratio
- PEPG N/A
- STTK N/A
- Revenue Growth
- PEPG N/A
- STTK 69.65
- 52 Week Low
- PEPG $0.88
- STTK $0.69
- 52 Week High
- PEPG $19.30
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- PEPG 41.13
- STTK 39.19
- Support Level
- PEPG $1.05
- STTK $0.77
- Resistance Level
- PEPG $1.49
- STTK $0.91
- Average True Range (ATR)
- PEPG 0.10
- STTK 0.08
- MACD
- PEPG -0.02
- STTK -0.02
- Stochastic Oscillator
- PEPG 38.64
- STTK 16.23
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.